Is there a bipartisan agreement to maintain exorbitant drug prices?

The rising expense of prescription pharmaceuticals is a common grievance among Americans, who also want some sort of control over these expenditures. Members of the Senate Special Committee on Aging chastised a number of top Valeant Pharmaceutical executives just last week for raising the costs of two heart and blood pressure medications, Isuprel and Nitropress, by 525 percent and 212%, respectively.